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ABSTRACT
Tumor necrosis factor-a (TNF-a) is known to play a role in the pathogenesis of graft-versus-host disease
(GVHD), a cause of significantmorbidity and treatment-relatedmortality (TRM) after allogeneic hematopoietic
stem cell transplantation (HCT).Wemeasured the concentration ofTNF-Receptor-1 (TNFR1) in the plasma of
HCT recipients as a surrogate marker for TNF-a both prior to transplant and at day 7 in 82 children who
underwent amyeloablative allogeneic HCT at the University ofMichigan between 2000 and 2005. GVHD grade
II–IV developed in 39% of patients at a median of 20 days after HCT. Increases in TNFR1 level at day 7 post-
HCT, expressed as ratios compared to pretransplant baseline, correlatedwith the severity ofGVHD (P5 .02). In
addition, day 7 TNFR1 ratios.2.5 baseline were associated with inferior 1-year overall survival (OS 51% versus
74%, P5 .04). As an individual biomarker, TNFR1 lacks sufficient precision to be used as a predictor for the de-
velopment of GVHD.However, increases in the concentration of TNFR1, which are detectable up to 2 weeks in
advance of clinical manifestations of GVHD, correlate with survival in pediatric HCT patients.
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Acute graft-versus-host disease (aGVHD) con-
tinues to be a leading cause of morbidity and mortality
following allogeneic hematopoietic stem cell trans-
plantation (HCT) in both adults and children [1,2].
Because no laboratory test predicts the development
of GVHD, clinical prognostic factors are used to de-
termine the risk of developing this complication.
Well-categorized GVHD prognostic factors include
donor age [3], donor type [4], and degree of human
leukocyte antigen (HLA) match [5]. Historically,
GVHDwas thought to occur less often in pediatric re-
cipients of HCT than in adult HCT recipients [6,7].
However, more recent large pediatric transplant stud-ies report rates of grade II-IV GVHD ranging from
40%-64%, similar to that seen in adults [8-12].
The pathophysiology of GVHD involves a com-
plex interaction between cellular immune effectors
such as donor T cells and host antigen-presenting cells
(APCs), and soluble effectors such as inflammatory cy-
tokines [13]. The role of tumor necrosis factor-alpha
(TNF-a) as a critical cytokine mediator of GVHD is
well established in murine models [14-18]. TNF-a is
produced by activated monocytes and macrophages,
as well as activated T cells [19]. Donor T cell-derived
TNF-a production appears to be a major contributor
to the incidence and severity of experimental GVHD
[20-22]. Significant increases in TNF-a levels have759
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and correlate with increased severity of GVHD [17].
In clinical allogeneic HCT, Holler and colleagues
[23-25] have shown an association between GVHD
and elevated levels of TNF-a during conditioning. Re-
cent evidence also suggests that inhibition of TNF-
a may be beneficial in patients as primary treatment
for aGVHD as well as in those with steroid refractory
aGVHD [24,26,27].
Given this data, we hypothesized that the concen-
tration of TNF-a would be elevated early after HCT
but prior to the development of GVHD in pediatric
recipients. Previous studies have shown that concen-
trations of TNF-a strongly correlate with concentra-
tions of tumor necrosis factor receptor 1 (TNFR1)
[28,29]. TNF-a binds to its receptors, TNFR1 and
TNFR2, on the surface of multiple cell types; the
receptor-ligand complexes are subsequently shed into
the plasma, where they are easily measured [30].
TNFR1 has superior stability than TNF-a in long-
term storage [25] and correlates with clinical GVHD
activity [26]. Therefore, we usedTNFR1 as a surrogate
marker for TNF-a.Wemeasured the concentration of
TNFR1 in samples obtained pre-HCT and at day 7
post-HCT in 82 pediatric patients who underwent
myeloablative allogeneic HCT at the University of
Michigan between January 2000 and December 2005.
MATERIALS AND METHODS
Patient Characteristics
Informed consent was obtained from the parent or
guardian of 82 children undergoing HCT under an institu-
tional review board-approved protocol between January
2000 and December 2005. Blood samples were obtained
prior to and at day 7 post HCT. The characteristics of these
patients are shown in Table 1. All patients received myeloa-
blative conditioning regimens. Donors and recipients were
considered matched if their HLA-A, B, and DR loci were
identical by midresolution DNA techniques for class I loci
and high-resolution techniques for class II loci. Cord blood
units were matched at 4 of 6 loci in 3 cases and 6 of 6 loci
in 3 cases. Hematologic malignancy was the indication for
transplantation in the 78% of patients. Donors included
HLA-identical siblings (n 5 32), single antigen mismatched
related donors (n 5 6), matched unrelated donors (n 5 35),
single antigen mismatched unrelated donors (n 5 3), and
unrelated cord blood units (n 5 6).
Prophylaxis, Diagnosis, and Treatment of GVHD
For prevention of GVHD, patients received tacrolimus
and either minidose methotrexate (5 mg/m2 on days 1, 3, 6,
and 11, n 5 76) or mycophenolate mofetil (MMF) (500
mg/m2/dose 3 times daily from day 0 to day 28, n 5 6).
Tacrolimus levels were monitored and the dose adjusted to
a target level of 8-12 ng/mL. The diagnosis of aGVHD
was based on clinical symptoms with confirmatory biopsies
from target organs obtained whenever clinically indicated
and appropriate. GVHDwas graded on a scale of 0-IV basedon the modified Glucksberg criteria [31]. Initial treatment of
clinically significant GVHD (overall grade $II) included
systemic methylprednisolone 2 mg/kg/day. Patients were
enrolled in clinical studies whenever possible, and those
who did not response to initial GVHD therapy received
additional agents at the discretion of the treating physician.
Supportive Care
All patients were admitted to HEPA filtered rooms. For
Pneumocystis jiroveci pneumonia prevention patients received
trimethoprim-sulfamethoxazole or pentamidine starting at
day 30 post-HCT. Acyclovir was given as prophylaxis for
patients seropositive for herpes simplex virus and/or vari-
cella-zoster virus. SerumCMVDNA levelsmeasured by poly-
merase chain reaction were tested weekly in recipients who
were seropositive or received a graft froma seropositive donor.
Antifungal prophylaxis consisted of fluconazole or voricona-
zole starting at the time of conditioning and continuing until
the patient was off immunosuppression. Patients received
leucoreduced and irradiated blood products to maintain their
hemoglobin.8.0 g/dL and platelet counts .20 k/mm3.
Table 1. Characteristics of 82 Pediatric Patients Who Underwent
a Myeloablative Allogeneic Transplant at the University of Michigan
between January 2000 and December 2005
Donor and Patient Age
Median patient age (range) n 5 82 8.8 years (0.8-17.8)
Median donor age (range) n 5 76* 21 years (0.6-55)
Diagnosis
Acute leukemia 62 (76%)
JMML 2 (2%)
Nonmalignant 18 (22%)
Disease stage
Standard risk 56 (87%)
High risk 8 (13%)
CMV status
Recipient 2/Donor 2 28 (34%)
Recipient 2/Donor 1 6 (7%)
Recipient 1/Donor 2 30 (37%)
Recipient 1/Donor 1 18 (22%)
Risk for CMV reactivation 54 (66%)
Conditioning
Busulfan-based† 52 (63%)
TBI-based‡ 23 (28%)
Cy/ATG§ 7 (9%)
Donor source
Related 38 (46%)
Unrelated 38 (46%)
Unrelated cord blood 6 (8%)
GVHD incidence
Grade 0-I 50 (61%)
Grade II 18 (22%)
Grade III-IV 14 (17%)
GVHD indicates graft-versus-host disease; JMML, juvenile myelo-
monocytic leukemia; TBI, total body irradiations.
*Six cord blood donors were excluded.
†Busulfan based: busulfan (12.8 mg/kg i.v.)/cyclophosphamide (120
mg/kg i.v.) 6 cytarabine (8 g/m2 i.v.).
‡TBI: (1200 cGy)/cyclophosphamide (120 mg/kg i.v.).
§Cy/ATG: cyclophosphamide (200 mg/kg i.v.)/antithymocyte glob-
ulin (7.5 mg/kg i.v.).
TNFR1 post-HCT Correlates with GVHD, OS in Children 761TNFR1 Measurement
On the day of sample acquisition, the plasma component
of each blood sample was separated and frozen for later anal-
ysis. The concentration of soluble TNFR1 was measured us-
ing a cytokine enzyme-linked immunosorbent assay (R&D,
Minneapolis, MN). The assays were performed according
to manufacturer’s protocol, and all samples and standards
were run in duplicate. The maximum GVHD scores were
blinded to the technician who ran the TNFR1 samples.
Statistical Analysis
Because of a 50-fold variability in baseline concentra-
tions of TNFR1 (143–7541 pg/mL), we expressed the day
7 value as a ratio to pretransplant baseline. Differences in
mean ratios of TNFR1 by GVHD grade were assessed using
univariate and multivariate linear regression models. Overall
survival (OS) was estimated using Kaplan-Meier methods,
and differences in OS among patient subgroups were as-
sessed with a log-rank test. P-Values of .05 or less were
considered statistically significant.
RESULTS
GVHD grade II-IV developed in 39% (95% con-
fidence interval [CI]: 29%, 50%) of patients at amedian
of 20 days (range: 8-72). The rate of severe grade III-IV
GVHD was 17% (95% CI: 10%, 27%). Baseline
TNFR1 concentrations did not correlate with the oc-
currence or severity ofGVHD, norwas there a correla-
tion between day 7 TNFR1 ratios and onset of GVHD
(P 5 .18). However, consistent with our hypothesis,
the mean day 7 TNFR1 ratio correlated with increased
severity of GVHD (Figure 1). In children who eventu-
ally developed a maximum of grade 0-I GVHD, the
mean day 7 ratio was 1.7 6 0.16 (n 5 50); those with
a maximum of grade II (n 5 18) the ratio was 2.4 6
0.68; and with maximum of grade III-IV (n 5 14) the
ratio was 3.06 0.62 (test for trend P5 .02). Increasing
mean day 7 TNFR1 ratios correlated with increasing
severity of GVHD; however, the sample size did not
permit demonstration of a significant correlation to
individual GVHD grades.
Because GVHD severity is an important predictor
ofmortality [1,32], we tested whether children with the
highest TNFR1 ratios experienced inferior survival.
The performance of TNFR1 as an individual bio-
marker for the prediction of GVHDwas assessed using
area under the receiver operating characteristic (ROC)
curve (AUC) (Figure 2). Multiple ratios between 1.35
and 2.74 demonstrated statistical significance in this
regard. We decided that a clinically meaningful
threshold should have a specificity of at least 80%
and the smaller group should include at least 1/5th
of the patients. Using these criteria, we found that
a threshold ratio of 2.5 was a useful discriminator
between groups (TNFR1 ratio.2.5, n5 19). As an in-
dividual biomarker for the prediction of GVHD,
a TNFR1 ratio of 2.5 corresponds to a specificity of82% and a sensitivity of 31%. Despite the low sensitiv-
ity of this test, the day 7 TNFR1 ratio significantly cor-
related with 1-year survival. Children with a day 7
TNFR1 ratio of #2.5 experienced 75% survival at 1
year (95% CI: 65%, 84%) compared to patients with
a ratio of .2.5 who experienced a statistically inferior
survival of 51% (95%CI: 41%, 62%) (Figure 3). As ex-
pected, patients with the higher day 7 TNFR1 ratios
had a higher incidence of GVHD grade II-IV and 1-
year nonrelapse treatment-related mortality (TRM),
but these differences did not reach the criteria for statis-
tical significance (Table 2). Rates of chronic GVHD
(cGVHD) were similar for patients with a day 7
TNFR1 ratio.2.5 or#2.5 (42% versus 38%, P5 .75).
The number of patients in this study was not suffi-
cient to simultaneously estimate the effects on GVHD
Figure 1. Mean day 7 ratios are associated with maximum severity
of GVHD (P 5 .02). Mean 6 SEM; Grade 0-I, 1.7 6 0.16; Grade
II, 2.4 6 0.68; Grade III-IV, 3.0 6 0.62.
Figure 2. ROC curve. The AUC of the ROC curve is 0.63, P5 .04.
The cross indicates a threshold ratio of 2.5 corresponding to a spec-
ificity of 82% and a sensitivity of 31%.
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donor age, CMV status (at risk for reactivation versus
no risk for reactivation), indication for transplant
(malignancy versus nonmalignancy) or disease status
(standard risk-leukemia in remission versus high risk-
leukemia not in remission) in a single multivariate
model. As an alternative, we fit 5 models using
GVHD grade combined separately with each of the
other patient characteristics. Thus, we could assess if
any of the patient characteristics individually altered
the association of the day 7 TNFR1 ratio with
GVHD grade. In 5 of these models (patient age, donor
age, CMV status, indication for transplant, and disease
status), the relationship between day 7 TNFR1 ratio
and GVHD remained significant after adjustment for
the other variable. However, after adjustment for do-
nor source, the day 7 TNFR1 ratio still correlated
with GVHD, but the association was no longer signif-
icant, indicating that the presence of confounding
between the day 7 ratio and donor source. In fact,
children who underwent an unrelated donor HCT
had higher mean day 7 TNFR1 ratios then children
who underwent a related donor HCT (2.6 versus 1.5,
P 5 .01). To further explore the relationship between
donor source and the day 7TNFR1 ratio on outcomes,
we divided the patients into 4 groups ordered from
lowest to highest according to expected risk of death:
related donor recipients with low day 7 TNFR1 ratios
(#2.5), related donor recipients with high day 7
TNFR1 ratios (.2.5), unrelated donor recipients
Figure 3. Kaplan-Meier plot of OS in children based on the day 7
TNFR1 threshold of 2.5 (P 5 .04).
Table 2. GVHD Grade II-IV Rates and 1 Year TRM Based on TNFR1
Day 7 Ratios # or .2.5
TNFR1 Ratio GVHD II-IV 1 Year TRM
TNFR1 #2.5 (n 5 63) 35% 8%
TNFR1 .2.5 (n 5 19) 53% 27%
P 5 .07 P 5 .09
TRM indicates treatment-relatedmortality; TNFR1, Tumor necro-
sis factor Receptor-1.with low day 7 TNFR1 ratios, and unrelated donor re-
cipients with high day 7 TNFR1 ratios, and compared
survival outcomes across these groups. The differences
in survival for these groups was statistically significant
(P 5 .01 by log rank analysis for trend), confirming
that a high day 7 TNFR1 ratio correlated with inferior
survival after stratification by donor source (Figure 4).
DISCUSSION
Because donor T cells are known to mediate
GVHD, effector mechanisms of GVHD damage ini-
tially focused primarily on the role of cytotoxic T lym-
phocytes. More recent animal models have suggested
that the clinical manifestations of GVHD are the cul-
mination of a series of complex interactions between
host APCs, donor T cells, and target tissues, all of
which are highly influenced by anti- and pro-inflam-
matory signals [13]. The validity of this model in chil-
dren has not previously been tested. In this study, we
report a significant association between the magnitude
of elevation of plasma TNFR1 concentrations at day 7
posttransplant and the subsequent severity of GVHD
in a series of 82 children who underwent myeloablative
allogeneic HCT. This evidence that a pro-inflamma-
tory environment early posttransplant influences
subsequent GVHD in pediatric HCT recipients is
strengthened by the finding that the magnitude of
change in TNFR1 concentrations correlates with like-
lihood of death in the first posttransplant year. Day 7
TNFR1 ratios .2.5 correlated with a 25% reduction
in survival over the first posttransplant year. Other
Figure 4. Kaplan-Meier plot of OS based on the day 7 TNFR1
threshold of 2.5 by donor source. MRD low5 recipients of matched
related donor HCT with a day 7 TNFR1 ratio #2.5, MRD high 5
recipients of matched related donor HCTwith a day 7 TNFR1 ratio
.2.5, MUD low 5 recipients of matched unrelated donor HCT
with a day 7 TNFR1 ratio#2.5,MUDhigh5 recipients of matched
unrelated donor HCT with a day 7 TNFR1 ratio.2.5. P5 .01, log
rank test for trend.
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the pretransplant marrow specimen, have correlated
with posttransplant survival probability [33-37].
In our pediatric patient population, there was
a trend toward a higher incidence of TRM in the
patients with TNFR1 ratios .2.5. In this study,
most of themortality is explained byGVHD, however,
other transplant related complications such as sepsis or
veno-occlusive disease (VOD) may contribute to both
TRM and elevated inflammatory TNFR1 concentra-
tions. In this study there were 3 cases of sepsis and 8
cases of VOD, resulting in 1 death. Therefore, a larger
study will be required to determine the relationship of
these less common complications to TNFR1 concen-
trations and outcomes.
Animal studies show that allogeneic reactions
between donor T cells and host APCs are established
within 72 hours of HCT [38]. Because the change in
day 7 TNFR1 concentrations predicted more severe
GVHD grade well in advance of its clinical manifesta-
tions, we speculate the TNFR1 ratio at this early time
point reflects the magnitude of the systemic alloreac-
tion that eventually culminates in clinical GVHD.
Our study was not designed to distinguish the individ-
ual contributions of the donor and recipient to
TNFR1 concentrations. Because most nucleated cells
express TNFR1[19], it is highly probable that both
donor and host cellular sources contribute to the
concentrations measured. Potential future clinical
studies could compare TNFR1 levels in autologous
transplant recipients to allogeneic recipients as an indi-
rect assessment of the recipient versus donor contribu-
tions of TNFR1. A potential complicating factor may
be the downregulation of recipient contributions to
TNFR1 concentrations over time by donor T cell
eradication of host TNF-a producing cells in the allo-
geneic setting.
We therefore speculate that the magnitude of in-
crease in TNFR1 concentration over baseline reflects
both host changes in response to myeloablative condi-
tioning, as well as donor cell responses to alloantigens
in the early posttransplant period. Not surprisingly,
these donor cell responses appear to be greater follow-
ing unrelated donor transplant as evidenced by higher
TNFR1 concentrations on day 7, presumably because
of increased likelihood of a robust donor-host interac-
tion given the greater number of minor histocompati-
bility mismatches in the unrelated donor setting.
Importantly, our study suggests that although unre-
lated donor recipients are more likely to have high
day 7 TNFR1 concentrations, any patient with
a high TNFR1 concentration at day 7 is at greater
risk of mortality, regardless of donor source. For ex-
ample, the expected survival advantage for related do-
nor recipients was offset by a high day 7 TNFR1 ratio
as evidenced by the nearly equivalent survival at 1 year
for related donor recipients with a high day TNFR1ratio and unrelated donor recipients with a low day
TNFR1 ratio.
Large numbers of children require allogeneic
HCT for treatment of high-risk or recurrent malig-
nancy. Because allogeneic HCT carries substantial
risk of treatment related morbidity and mortality,
further improvement in survival rates in pediatric allo-
geneic HCT recipients depends in part on further
advances in the diagnosis, prevention, and treatment
of transplant-related complications such as GVHD.
Our findings suggest that it may be possible to develop
prognostic biomarkers for GVHD. Validation of these
observations in a multicenter setting, perhaps with
a larger panel of candidate proteins, should be pur-
sued. Development of a predictive laboratory test for
GVHD may allow risk-stratification early after HCT
and provide the rationale for more individualized
preemptive treatment strategies that may eventually
improve OS of these patients.
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